metronidazole has been researched along with Sensation Disorders in 2 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 53-year-old male patient developed insidious onset of length-dependent painful neuropathy on a background of encephalopathy during prolonged treatment with metronidazole for a cumulative dose of 146 g in 88 days." | 7.77 | Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. ( Chao, CC; Chen, CC; Chen, YF; Hsieh, ST; Liou, HH; Tan, CH, 2011) |
| "A 53-year-old male patient developed insidious onset of length-dependent painful neuropathy on a background of encephalopathy during prolonged treatment with metronidazole for a cumulative dose of 146 g in 88 days." | 3.77 | Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. ( Chao, CC; Chen, CC; Chen, YF; Hsieh, ST; Liou, HH; Tan, CH, 2011) |
| "Metronidazole is a widely prescribed treatment for amoebic and anaerobic germ infections." | 1.35 | [Metronidazole-induced reversible cerebellar lesions and peripheral neuropathy]. ( Essid, A; Hammouda, M; Laouani-Kechrid, C; Medimagh, L; Slamia, LB; Toumi, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toumi, S | 1 |
| Hammouda, M | 1 |
| Essid, A | 1 |
| Medimagh, L | 1 |
| Slamia, LB | 1 |
| Laouani-Kechrid, C | 1 |
| Tan, CH | 1 |
| Chen, YF | 1 |
| Chen, CC | 1 |
| Chao, CC | 1 |
| Liou, HH | 1 |
| Hsieh, ST | 1 |
2 other studies available for metronidazole and Sensation Disorders
| Article | Year |
|---|---|
[Metronidazole-induced reversible cerebellar lesions and peripheral neuropathy].
Topics: Adult; Brain Abscess; Cerebellar Diseases; Consciousness Disorders; Humans; Magnetic Resonance Imagi | 2009 |
Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity.
Topics: Denervation; Humans; Magnetic Resonance Imaging; Male; Metronidazole; Middle Aged; Neural Conduction | 2011 |